Written By | Health News Agencies
Then mRNA technology stunned the world during the pandemic — and scientists turned the same tools loose on cancer
Search
NEW YORK
For decades, "cancer vaccine" lived in the same drawer as flying cars. Then mRNA technology stunned the world during the pandemic — and scientists turned the same tools loose on cancer. Now the longest look yet at one of those experimental shots has landed, and it's turning cautious oncologists into believers.
Five years after patients with high-risk melanoma had their tumors removed, a personalized mRNA cancer vaccine — paired with the immunotherapy drug Keytruda — was still cutting the risk of the cancer returning or killing them by 49% compared with Keytruda alone. Not at six months. Not at a year. At five full years.
And the protection had barely budged from where it stood at year three.
A vaccine built just for you
Unlike a flu shot, this vaccine is custom-built from a single patient's own tumor. Scientists analyze the removed melanoma, hunt for "neoantigens" (mutated proteins unique to that cancer), and design mRNA coding for up to 34 of these flags. Injected into the patient, it trains the immune system to hunt those exact cancer cells.
Keytruda takes the brakes off the immune system so the newly trained T cells can attack. Name the target. Unleash the attack.
The numbers behind the headline
From the Phase 2b trial (KEYNOTE-942) in high-risk Stage III or IV melanoma patients whose tumors were surgically removed:
After five years:
Side effects: fatigue, injection-site soreness, chills — manageable, not the brutal toll of traditional cancer therapy.
Why melanoma — and what comes next
Melanoma is mutation-riddled, throwing off rich neoantigen targets. It's also a cancer the immune system already "sees" relatively well. Add a personalized vaccine, and you get the synergy in these results.
A large Phase 3 trial is already underway in melanoma. Crucially, researchers are testing the same approach against lung cancer and other tumors. If it works across multiple cancers, the implications are staggering: a bespoke vaccine for every patient, designed to stop the cancer from ever coming back.
Expert perspective
The durability impresses most. Many cancer therapies show early benefit that fades. Seeing the protection hold from year three to year five suggests the immune system is forming lasting memory.
Caveats: Phase 2 was relatively small (~150 patients). Personalized manufacturing is complex and costly. Phase 3 confirmation is needed.
Still — after years of hype, here is a personalized cancer vaccine with five years of human data showing a benefit that doesn't evaporate. That's no longer a promise. It's a result.
What this means for you
This vaccine is not yet approved. It remains investigational, available only through clinical trials.
If you or a loved one faces high-risk melanoma after surgery, ask your oncology team about trial enrollment. That's how patients access cutting-edge therapies years before they reach the wider market.
And the oldest advice still matters: sun protection, no tanning beds, check new or changing moles. Early detection still saves more lives than any therapy.
The bottom line
Five years of follow-up have transformed a hopeful idea into a landmark result: a personalized mRNA vaccine that cut the risk of high-risk melanoma returning or killing patients by 49% — and held that protection steady for half a decade, while slashing metastasis risk by 59%.
The era of the "cancer vaccine" being perpetually ten years away may finally be ending. The future of treatment may be a shot designed for an audience of one.
